Olean Times Herald

SUMMIT, N.J. , March 18, 2025 /PRNewswire/ -- A 60-patient, randomized, double-blind, placebo-controlled phase I clinical study of VAS101 (topical cur...

SUMMIT, N.J. , March 17, 2025 /PRNewswire/ -- In a new study published in the journal GeroScience, VAS101 (Vasceptor®), a novel curcumin transdermal f...

SUMMIT, N.J. , Feb. 18, 2025 /PRNewswire/ -- An article in the Proceedings of the National Academy of Sciences (PNAS) Nexus journal* by Goel et al. de...

SUMMIT, N.J. , Jan. 13, 2025 /PRNewswire/ -- Vascarta has obtained the exclusive rights to a novel method of creating more effective cancer therapies ...